Drug profile · INN
nogapendekin alfa inbakicept-pmln
ANKTIVA
nogapendekin alfa inbakicept-pmln (ANKTIVA) is a interleukin-15 receptor agonist. Route of administration: intravesical. Current US regulatory status: approved.
Drug details — nogapendekin alfa inbakicept-pmln
- US status
- approved
- Class
- —
- Route
- INTRAVESICAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
nogapendekin alfa inbakicept-pmln (ANKTIVA) is a interleukin-15 receptor agonist. Route of administration: intravesical. Current US regulatory status: approved.
Key facts
Mechanism of action
Interleukin-15 receptor agonist
Primary target: Interleukin-15 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
ImmunityBio's Anktiva Expansion: Navigating FDA Decision Dates and Regulatory Hurdles
ImmunityBio is navigating a complex regulatory landscape for its bladder cancer therapy, Anktiva. This article provides insights into upcoming FDA decisions and their impact on the pharmaceutical industry.
ImmunityBio's Anktiva Expansion: FDA Decision Date Insights
ImmunityBio has secured a decision date from the FDA regarding Anktiva's expansion. This article explores the implications for pharma stakeholders.
ImmunityBio Faces Securities Fraud Lawsuit Over Anktiva Off-Label Promotion After FDA Warning Letter
ImmunityBio hit with class action lawsuit after FDA determined company made false claims about Anktiva bladder cancer drug's capabilities beyond approved use.
ImmunityBio (IBRX) Faces FDA Warning Letter and Class Action Lawsuit Over Anktiva Claims
ImmunityBio faces securities lawsuit after FDA warning letter regarding executive claims about lead immunotherapy drug Anktiva, impacting investor confidence.
Related & competitor drugs
Frequently asked questions
What is nogapendekin alfa inbakicept-pmln?
nogapendekin alfa inbakicept-pmln (ANKTIVA) is a interleukin-15 receptor agonist. Route of administration: intravesical. Current US regulatory status: approved.
What is the brand name for nogapendekin alfa inbakicept-pmln?
ANKTIVA is a marketed brand name for nogapendekin alfa inbakicept-pmln. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of nogapendekin alfa inbakicept-pmln?
nogapendekin alfa inbakicept-pmln has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.